Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 3:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Anaplastic Lymphoma Kinase Clear all
Recruiting Phase 1Phase 2 Interventional

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626
View directory record Official record
Conditions
Locally Advanced Solid Tumor, Metastatic Solid Tumor
Interventions
Neladalkib (NVL-655), Midazolam, Repaglinide, Itraconazole
Drug
Lead sponsor
Nuvalent Inc.
Industry
Eligibility
12 Years and older
Enrollment
840 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Orange, California • Sacramento, California • Stanford, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

NCT02521051
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC)
Interventions
Alectinib, Bevacizumab
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 1 Interventional Results available

A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase

NCT01283516
View directory record Official record
Conditions
Tumors Characterized by Genetic Abnormalities of ALK
Interventions
LDK378
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2019 · Synced Jun 25, 2026, 3:18 PM EDT
Active, not recruiting Phase 1 Interventional

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

NCT02321501
View directory record Official record
Conditions
ALK Positive, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, ROS1 Gene Rearrangement, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions
Ceritinib, Everolimus, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

NCT02846792
View directory record Official record
Conditions
ALK Gene Translocation, EGFR Activating Mutation, Recurrent Non-Small Cell Lung Carcinoma, ROS1 Gene Translocation, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
Interventions
Nivolumab, Plinabulin
Biological · Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jun 25, 2026, 3:18 PM EDT
Recruiting Phase 1 Interventional

A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)

NCT07140016
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Anaplastic Lymphoma Kinase (ALK) Positive
Interventions
gilteritinib
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
8
States / cities
Orange, California • Atlanta, Georgia • Peoria, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma

NCT00939770
View directory record Official record
Conditions
Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma
Interventions
Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study, Questionnaire Administration
Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 21 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
27
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2020 · Synced Jun 25, 2026, 3:18 PM EDT
Terminated Phase 1 Interventional

A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC

NCT04849273
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Non-Small Cell Lung Cancer, NSCLC, Advanced Solid Tumor, Metastatic Solid Tumor, ALK Gene Mutation
Interventions
TPX-0131
Drug
Lead sponsor
Turning Point Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
7
States / cities
Orange, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated May 25, 2023 · Synced Jun 25, 2026, 3:18 PM EDT
Terminated Phase 1 Interventional

Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

NCT04005144
View directory record Official record
Conditions
ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
Interventions
Binimetinib, Brigatinib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2022 · Synced Jun 25, 2026, 3:18 PM EDT
Active, not recruiting Phase 2 Interventional

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

NCT02568267
View directory record Official record
Conditions
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
Interventions
Entrectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
53
States / cities
Phoenix, Arizona • Duarte, California • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 3 Interventional Results available

An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

NCT00932893
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
PF-02341066, Pemetrexed, Docetaxel
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
119
States / cities
Little Rock, Arkansas • Bakersfield, California • Beverly Hills, California + 58 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 2 Interventional

A Study of Ganetespib in Subjects With ALK-Positive Non-Small-Cell Lung Cancer (NSCLC)

NCT01562015
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Ganetespib
Drug
Lead sponsor
Synta Pharmaceuticals Corp.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Tampa, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 2 Interventional Results available

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

NCT03647488
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Capmatinib, Spartalizumab, Docetaxel
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2022 · Synced Jun 25, 2026, 3:18 PM EDT
Active, not recruiting Phase 1 Interventional

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

NCT02393625
View directory record Official record
Conditions
ALK-positive NSCLC
Interventions
Ceritinib (LDK378), Nivolumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
4
States / cities
Scottsdale, Arizona • Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

NCT06362369
View directory record Official record
Conditions
Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis, Pleural Mesothelioma, Renal Cell Carcinoma, MSI-High, Mismatch Repair Deficiency, Colorectal Cancer, Hepatocellular Carcinoma, Hepatocellular Cancer, Renal Cell Cancer, Kidney Cancer, Skin Cancer, Non Small Cell Lung Cancer, NSCLC, Anaplastic Lymphoma Kinase Genomic Tumor Aberrations, ALK Genomic Tumor Aberrations
Interventions
Alintegimod, Ipilimumab, Nivolumab
Drug
Lead sponsor
7 Hills Pharma, LLC
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
5
States / cities
Aurora, Colorado • Lake Mary, Florida • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 4 Interventional Results available

Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

NCT04362072
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Lorlatinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 10, 2025 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 3 Interventional

A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer

NCT03194893
View directory record Official record
Conditions
Neoplasms
Interventions
Alectinib, Crizotinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Orange, California • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 1 Interventional

Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer

NCT01772797
View directory record Official record
Conditions
Anaplastic Lymphoma Kinase (ALK), Non-small Cell Lung Cancer
Interventions
LDK378, AUY922
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Boston, Massachusetts • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jun 25, 2026, 3:18 PM EDT
Active, not recruiting Phase 1 Interventional

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

NCT03707938
View directory record Official record
Conditions
Advanced Lung Carcinoma, ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Brigatinib, Local Consolidation Therapy
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jun 25, 2026, 3:18 PM EDT
Active, not recruiting Phase 3 Interventional Results available

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

NCT03456076
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Alectnib, Cisplatin, Vinorelbine, Gemcitabine, Pemetrexed, Carboplatin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
257 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2031
U.S. locations
3
States / cities
Chicago, Illinois • Boston, Massachusetts • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Withdrawn Phase 2 Interventional

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

NCT03868423
View directory record Official record
Conditions
Advanced Malignant Neoplasm, ALK Fusion Protein Expression, ALK Gene Amplification, ALK Gene Mutation, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Central Nervous System, Metastatic Malignant Solid Neoplasm, ROS1 Fusion Positive, ROS1 Gene Amplification, ROS1 Gene Mutation
Interventions
Brigatinib, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jun 25, 2026, 3:18 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

NCT01871805
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Alectinib
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
39
States / cities
Birmingham, Alabama • Irvine, California • La Jolla, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Jun 25, 2026, 3:18 PM EDT
Terminated Phase 2 Interventional Results available

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

NCT04676360
View directory record Official record
Conditions
Relapsed Plasmablastic Lymphoma, Refractory Plasmablastic Lymphoma, Anaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Interventions
Belantamab Mafodotin
Drug
Lead sponsor
Jacob Soumerai, MD
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Jun 25, 2026, 3:18 PM EDT
Active, not recruiting Not applicable Interventional

Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies

NCT05370469
View directory record Official record
Conditions
Lung Cancer, EGFR Gene Mutation, EGFR, ALK Gene Mutation, RET Gene Mutation, MET Gene Mutation, KRAS Mutation-Related Tumors, BRAF, ROS1 Gene Mutation
Interventions
Sensus Smartwatch Application, RX Cap, Fitbit Sense, Surveys
Other · Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Jun 25, 2026, 3:18 PM EDT